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Introduction: Amino-bisphosphonates and statins inhibit the mevalonate pathway, and may exert anti-tumor
effects. The Wnt inhibitor dickkopf-1 (DKK-1) promotes osteolytic bone lesions by inhibiting osteoblast functions
and has been implicated as an adverse marker in multiple cancers. We assessed the effects of mevalonate pathway
inhibition on DKK-1 expression in osteotropic breast cancer.
Methods: Regulation of DKK-1 by bisphosphonates and statins was assessed in human breast cancer cell lines, and
the role of the mevalonate pathway and downstream targets was analyzed. Moreover, the potential of breast cancer
cells to modulate osteoblastogenesis via DKK-1 was studied in mC2C12 cells. Clinical relevance was validated by
analyzing DKK-1 expression in the tissue and serum of women with breast cancer exposed to bisphosphonates.
Results: DKK-1 was highly expressed in receptor-negative breast cancer cell lines. Patients with receptor-negative
tumors displayed elevated levels of DKK-1 at the tissue and serum level compared to healthy controls. Zoledronic
acid and atorvastatin potently suppressed DKK-1 in vitro by inhibiting geranylgeranylation of CDC42 and Rho.
Regulation of DKK-1 was strongest in osteolytic breast cancer cell lines with abundant DKK-1 expression. Suppression of
DKK-1 inhibited the ability of breast cancer cells to block WNT3A-induced production of alkaline phosphates and
bone-protective osteoprotegerin in preosteoblastic C2C12 cells. In line with the in vitro data, treatment of breast cancer
patients with zoledronic acid decreased DKK-1 levels by a mean of 60% after 12 months of treatment.
Conclusion: DKK-1 is a novel target of the mevalonate pathway that is suppressed by zoledronic acid and atorvastatin
in breast cancer.Introduction
Bone metastases remain a serious long-term complication
in patients suffering from breast cancer and prostate can-
cer. Bisphosphonates (BPs) are established antiresorptive
agents for the treatment of bone metastases. More re-
cently, direct antitumor effects of BPs have been suggested,
including induction of apoptosis and inhibition of migra-
tion, invasion, and (neo) vascularization [1]. BPs with anti-
tumor activity are generally nitrogen-containing BPs that
inhibit farnesyl pyrophosphate synthase, a key enzyme of
the mevalonate pathway [2,3]. Statins are a second group
of clinically established agents that inhibit the mevalonate
pathway and have also been associated with an antitumor* Correspondence: Tilman.rachner@uniklinikum-dresden.de
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reproduction in any medium, provided the orpotential [4]. Hence, a number of clinical trials were initi-
ated to investigate whether these promising preclinical re-
sults would translate into clinical efficacy for women with
nonmetastatic breast cancer. Although modestly favoring
the adjuvant use of bisphosphonates, these trials failed to
provide a clear evidence for their general efficacy in adju-
vant therapy. Of note, positive results were repeatedly re-
ported for women with deprived estrogen levels as a result
of menopause or hormone ablation therapy [5-8].
Dickkopf-1 (DKK-1), a soluble inhibitor of the canon-
ical Wnt signaling pathway, has been linked to osteolytic
bone disease [9]. In multiple myeloma, increased levels
of DKK-1 are associated with the presence of lytic bone
lesions [10]. DKK-1 is thought to promote osteolytic
bone disease directly by inhibition of osteoblasts and
concurrently promoting osteoclasts via suppression of
osteoprotegerin (OPG) and enhancing receptor activatorl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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loma, inhibition of DKK-1 reduced the extent of osteolytic
lesions [12,13]. In contrast to myeloma bone disease, the
role of DKK-1 in breast cancer and prostate cancer is less
clear. In metastatic breast cancer, serum levels of DKK-1
are increased [14], and breast cancer-derived DKK-1 has
the ability to inhibit osteoblast differentiation [15]. In
women with triple-negative breast cancer, which is associ-
ated with a high risk of recurrence, expression of DKK-1
indicated poor outcome of patients [16]. In prostate can-
cer, DKK-1 expression increases in early stages while de-
creasing during progression towards metastatic disease
[17]. These data indicate that DKK-1 may have a patho-
physiological role in skeletal metastases of breast and
prostate cancer. Here we identified DKK-1 as a novel tar-
get of the mevalonate pathway in estrogen receptor (ER)-
negative breast cancer that can be modulated by BPs and
statins via inhibiting of geranylgeranylation.
Methods
Cells
Breast cancer cells (MDA-MB-231, MCF-7 and T47D) and
prostate cancer cells (PC-3 and MDA-PCa2b) were pur-
chased from ATCC (Manassas, VA, USA), except for
MDA-BONE cells (also known as MB-231-TxSA) that were
obtained from the University of Texas (San Antonio, TX,
USA) and MDA-MET cells that were a kind gift from Prof.
L Suva (Center for Orthopaedic Research, University of Ar-
kansas AR, USA). For osteoblast experiments, the murine
myoblast cell line mC2C12 was used. C2C12 cells are a
murine myoblast cell line capable of differentiation towards
osteoblasts in the presence of Wnt ligands. Murine C2C12,
control L-cells and WNT3A-L-Cells were a kind gift from
Dr Michael Stock (University of Erlangen, Germany). Pros-
tate cancer cell lines were kept in RPMI 1640 medium from
Bio West (Renningen, Germany). All other cell lines were
cultured in Dulbecco’s modified Eagle’s medium/Ham’s
F-12 (PAA, Pasching, Austria), 10% fetal calf serum supreme
(Lonza, Cologne, Germany) and 1% penicillin/streptomycin
(PAA). Human microvascular endothelial cells-1 were cul-
tured in endothelial cell growth medium 2 (PromoCell,
Heidelberg, Germany). Primary cultures of human umbi-
lical vein endothelial cells were isolated using collagenase
II as described previously [18]. All cell lines that were
not purchased from ATCC were obtained following the
ethical guidelines of our institution and the providing
institution. Cell lines were sent to DSMZ (German Collection
of Microorganisms and Cell Culturs), where authenticity
was determined by short tandem repeat profiling and by
matching with the known profiles.
Small interfering RNA, antibodies and reagents
Zoledronic acid was provided by Novartis (Basel,
Switzerland), and atorvastatin, mevalonate, geranyl-geranyl-pyrophosphate (GGPP), farnesyl pyrophosphate
(FPP), GGTI-298 and FTI-277 were obtained from
Sigma-Aldrich (Munich, Germany). Rac1 inhibitors #1
(553502) and #2 (553511), Y-27632, rho kinase inhibitor
(H-1152P) and Clostridium difficile toxin A were from
Merck Chemicals (Darmstadt, Germany). Cdc42 inhibi-
tor ML-141 was from Tocris Bioscience (Bristol, UK).
Rho inhibitor #2 (BML-EI394) was obtained from Enzo
(Lörrach, Germany). Rho inhibitor #1 (CT04) and Rho/
Rac/Cdc42 activator I were from Cytoskeleton Inc.
(Denver, CO, USA). Recombinant human DKK-1 was
obtained from Peprotech (Hamburg, Germany). Antibody
for RAP1A (sc-1482) was from Santa Cruz (Heidelberg,
Germany), RAS (610001) antibody was from BD Biosci-
ences (Heidelberg, Germany), the DKK-1 (MAB10962)
antibody was from R&D Systems (Wiesbaden, Germany)
and all other antibodies were obtained from Cell Signaling
Technology (Frankfurt, Germany). DKK-1 small interfer-
ing RNA (siRNA; s22721 and s22723), Cdc42 siRNAs and
nontarget siRNA were purchased from Applied Biosys-
tems (Darmstadt, Germany). Cells were transfected using
Dharmafect (Thermo Scientific, Waltham, Massachusetts
(MA) USA).RNA isolation, reverse transcription and real-time
polymerase chain reaction
RNA from cell cultures was isolated using the High-
Pure RNA extraction kit from Roche Applied Science
(Mannheim, Germany) according to the manufacturer’s
protocol. RNA (500 ng) was reverse transcribed using
Superscript II (Life Technologies, Darmstadt, Germany)
and used for SYBR green-based real-time polymerase
chain reaction (PCR) using a standard protocol (Applied
Biosystems). Primer sequences were: hu glyceraldehyde
3-phosphate dehydrogenase (GAPDH) sense, AGCCA
CATCGCTCAGACAC; hu GAPDH antisense, GCCCAA
TACGACCAAATCC; hu Dkk-1 sense, AGCACCTTG
GATGGGTATTC; hu DKK-1 antisense, CACACTT
GACCTTCTTTCAGGAC; mu ACTB sense, GATCTGG
CACCACACCTTCT; mu ACTB antisense, GGGGTG
TTGAAGGTCTCAAA; mu ALP sense, CTGGTGGCAT
CTCGTTATCC; mu ALP antisense, CTACTTGTGTG
GCGTGAAGG; and mu OPG sense, CCTTGCCCTGAC
CACTCTTA; mu OPG antisense, CCTTGCCCTGAC
CACTCTTA. PCR conditions were 50°C for 2 minutes
and 95°C for 10 minutes followed by 40 cycles with 95°
C for 15 seconds and 60°C for 1 minute. The melting
curve as assessed in the following program: 95°C for
15 seconds, 60°C for 1 minute and 95°C for 30 seconds.
The results were calculated applying the ΔΔCT method
and are presented as the x-fold increase relative to the
housekeeping gene (GAPDH or β-actin) or as a percent-
age of control.
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The human WNT signaling pathway PCR array (PAHS-
0437; QIAGEN, Hilden, Germany) was used to screen for
Wnt-related targets and was performed using the provided
protocols. Briefly, cDNA templates of zoledronic acid-
treated and control-treated MDA-231 cells were mixed
with the appropriate PCR master mix. Equal volumes were
pipetted to each well of the same PCR array. PCRs were
performed as described above. Assessment of three indi-
vidual experiments was conducted using the software pro-
vided by the manufacturer.
cDNA polymerase chain reaction array
The breast cancer cDNA Array II was purchased from
Origene (Rockville, MD, USA) and was assessed for
DKK-1 expression, normalized to GAPDH using the
supplier’s protocol. This array contains 48 samples, cov-
ering five normal breast tissues and 43 samples of breast
cancer, and provides clinical information including hor-
mone status and pathological grade.
Dickkopf-1 and osteoprotegerin enzyme-linked
immunosorbent assay and serum markers of bone turnover
Human DKK-1 and murine OPG enzyme-linked immuno-
sorbent assays were obtained from Biomedica (Vienna,
Austria) and were performed according to the manufac-
turer’s instructions. Cell supernatants were prediluted as
determined by pretesting. Serum samples of breast cancer
patients and healthy controls were obtained after in-
formed consent and Institutional Review Board approval.
Details of patient characteristics are shown in Figure S3B
in Additional file 1. Patients were women with hormone-
negative, nonmetastatic, breast cancer who were blinded
to receive infusions of either 4 mg zoledronic acid or pla-
cebo every 3 months as adjuvant therapy. These patients
received 1,000 mg calcium and 1,000 IU vitamin D per
day for the duration of the study after Institutional Review
Board approval (97/05 (A)/KKS 1009 and informed pa-
tient consent had been obtained. Detailed patient charac-
teristics are shown in Figure S4A in Additional file 1. No
additional concomitant drugs known to influence bone
turnover were given. Control serum was taken before the
first administration of zoledronic acid and before each fur-
ther administration. Blood samples were immediately
worked up and stored at −80°C until the analyses were
performed. Markers of bone turnover were measured as
routine parameters by our clinical laboratory.
Immunoblotting
Western blot analyses were performed as described previ-
ously [19]. Briefly, after completion of the experiments,
cells were lysed and quantified. In general, 20 μg protein
were loaded for SDS-PAGE and transferred onto a 0.2 μm
nitrocellulose membrane. After blocking for 1 hour with5% nonfat dry milk in Tris-buffered saline with 1% Tween-
20, membranes were incubated with a primary antibody
overnight. After washing, the membrane was incubated for
1 hour with the horseradish peroxidase-conjugated second-
ary antibody. Membranes were then washed three times
with Tris-buffered saline with 1% Tween-20, and proteins
were visualized with Super Signal (Pierce, Bonn, Germany)
enhanced chemiluminescence.
Immunohistochemistry and quantitative assessment
Primary breast cancer tissue was assessed using immu-
nohistochemistry. Multiple tissue microarrays (TMA
8501) were purchased from Tristar (Rockville, MD, USA).
Paraffin-embedded sections were dewaxed, rehydrated
using an alcohol gradient, and heat-retrieved from anti-
gens. Endogenous peroxidase activity was blocked using
0.3% H2O2/phosphate-buffered saline for 10 minutes at
room temperature and nonspecific binding sites using the
blocking buffer of the VECTASTAIN Elite ABC Kit (VEC-
TOR Laboratories, Peterborough, UK) for 45 minutes at
room temperature. Afterwards, sections were incubated
with a polyclonal anti-DKK-1 antibody (ab22827; Abcam,
Milton, UK) overnight at 4°C. Subsequently, slides were
treated with an anti-goat secondary antibody conjugated
to biotin and then developed utilizing avidin-conjugated
horseradish peroxidase with diaminobenzidine as sub-
strate (DAKO, Hamburg, Germany). Specificity was vali-
dated in cell sections where DKK-1 levels were diminished
using siRNA (Figure S3A in Additional file 1). Staining in-
tensity was assessed by two individual and experienced pa-
thologists (MHM and GBB) and rated as either none (0),
weak (1), moderate (2) or strong (3). Interobserver vari-
ability was measured using the Cohen’s κ test.
Statistical analysis
Results are presented as the mean ± standard deviation.
All experiments were repeated at least three times. Statis-
tical evaluations were performed using a one-way analysis
of variance or Student’s t test. P < 0.05 was considered sta-
tistically significant.
Results
Dickkopf-1 expression is suppressed by zoledronic acid
and atorvastatin in breast cancer cell lines in vitro
To identify novel targets of zoledronic acid, a Wnt signal-
ing pathway PCR array was conducted with MDA-231
breast cancer cells after 24 hours of treatment with zole-
dronic acid. Eleven genes were regulated more than two-
fold (Figure 1A; full list of genes shown in Figure S1A in
Additional file 1). DKK-1 was the utmost regulated gene,
with a sevenfold suppression. To further assess the under-
lying mechanism(s) of this observation, baseline expres-
sion of DKK-1 was assessed in multiple breast cancer and
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Figure 1 Dickkopf-1 is a target of zoledronic acid and atorvastatin in breast cancer cells in vitro. (A) Results from a WNT PCR array define
Dickkopf-1 (DKK-1) as a target of zoledronic acid. MDA-231 cells were treated with zoledronic acid (100 μM) for 24 hours and assessed by a WNT
array. A heat map of all tested genes is shown on the right: green, increased expression compared with control; red, decreased expression compared
with control; grey, nondetectable gene. All genes that were regulated at least twofold are separately depicted on the left. (B) Basal expression of DKK-1
in different breast cancer cell lines assessed by polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA) and western Blot.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is a loading control. (C), (D) Suppression of DKK-1 by zoledronic acid (ZOL; 100 μM) and
atorvastatin (ATO; 10 μM) after 24 hours of exposure was confirmed in multiple cell lines. Assessment of unfarnesylated RAS (upper band) and
ungeranylated RAP1A confirmed mevalonate pathway inhibition. Representative blots are shown. GAPDH is used as a loading control. Data for PCR
and ELISA are shown as mean ± standard deviation of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
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of DKK-1 was approximately 10-fold to 100-fold higher in
the ER-negative and highly metastatic MDA-231, MDA-
BONE and MDA-MET cell lines, compared with ER-
positive MCF-7 and T47D cells (Figure 1B).
Next, suppression of DKK-1 by zoledronic acid was
confirmed in these cell lines. The most potent inhibitory
effects of DKK-1 by zoledronic acid (100 μM) were ob-
served in those cell lines with the highest constitutive
expression of DKK-1 (Figure 1C). Successful blockade of
the mevalonate pathway was confirmed by western blot
detection of unprenylated RAS and RAP1A, which are
exclusively farnesylated (RAS) and geranylated (RAP1A)
downstream targets of the mevalonate pathway.
The same cell lines were then exposed to 10 μM ator-
vastatin for 24 hours, which resulted in a comparableaccumulation of unprenylated RAS and RAP1A, indicat-
ing potent inhibition of the mevalonate pathway. Ator-
vastatin reduced DKK-1 expression as seen previously
with zoledronic acid (Figure 1D). Of note, zoledronic
acid and atorvastatin failed to reduce DKK-1 expression
in ER-positive T47D cells, the cell line that also dis-
played the lowest basal DKK-1 levels.
Both zoledronic acid and atorvastatin caused a dose-
dependent inhibition of DKK-1 in MDA-231 cells
(Figure S2A,B in Additional file 1). In zoledronic acid-
treated cells, modest effects were seen starting at 10 μM.
In the case of atorvastatin, concentrations of 1 μM were
sufficient to significantly suppress DKK-1 (P < 0.01). Inter-
estingly, 2-hour exposure to zoledronic acid resulted in a
reduction of DKK-1 24 hours later that was comparable
with continuous exposure (Figure S2C in Additional file 1).
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lowing the same protocol (2-hour exposure, measurement
24 hours later), indicating different mechanisms of cellular
uptake (data not shown).
To analyze whether suppression of DKK-1 is limited to
breast cancer cells, we also assessed DKK-1 levels in pros-
tate cancer cells and endothelial cells following exposure
to zoledronic acid and atorvastatin. In line with the pro-
posed effect of DKK-1 exposure on osteoblast inhibition,
PC3 cells, which form osteolytic lesions in vivo, showed
high baseline levels of DKK-1, whereas MDA-PCa 2b
cells, which have an osteoblastic phenotype, had low
DKK-1 expression (Figure S1B in Additional file 1). Treat-
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Figure 2 Dickkopf-1 expression in breast cancer samples and serum.
tissue microarray consisting of 74 breast cancer samples and 10 normal tiss
DKK-1 and staining was graded from none (0) to strong (3). (B) A cDNA br
cancer. Expression of DKK-1 was measured and normalized to β-actin. (C) D
receptor (ER)-negative breast cancer (n = 28) or in healthy controls (n = 27).reduced DKK-1 expression levels in PC3 cells. Similar ef-
fects were seen in human microvascular endothelial cells-
1 and human umbilical vein endothelial cells (Figure S1C,
D in Additional file 1). These findings indicate that regula-
tion of DKK-1 by BPs and statins is a more general effect
that is not specific to breast cancer.
Dickkopf-1 is overexpressed in estrogen receptor-
negative primary breast cancer
Immunohistochemical staining of primary breast cancer tis-
sue revealed a medium to strong expression of DKK-1 in
70% (52/74) of evaluated breast cancer cases, mainly in the
cytoplasm. Of note, DKK-1 protein expression in normal



























(A) Dickkopf-1 (DKK-1) expression was assessed in a breast cancer
ues. The TMA was stained with an antibody directed against human
east cancer array was used to quantify DKK-1 expression in breast
KK-1 serum levels are elevated (P = 0.006) in patients with estrogen
Patients’ characteristics are listed in Figure S3B in Additional file 1.
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DKK-1 expression in a cohort of 43 breast cancer patients
and five healthy controls showed increased expression of
DKK-1 mRNA in many tumors compared with control,
with no correlation between DKK-1 and tumor stage (data
not shown). However, when correlated with the ER status,
we found DKK-1 expression to be considerably higher in
ER-negative tumors than in other samples (Figure 2B).
While the mean expression of DKK-1 (relative to β-actin)
was unchanged in patients with ER-positive tumors
compared with normal breast tissue, it was increased
by 21-fold in ER-negative samples. To test whether
these findings translated into relevant changes at serum
level, we measured DKK-1 levels in patients with ER-
negative (nonmetastatic) breast cancer and compared
them with a matched cohort (age, body mass index and
menopausal status; Figure S3B in Additional file 1) of
healthy controls. While healthy controls had mean
DKK-1 serum levels of 23.8 pmol/l (n = 27), these levels
significantly increased to 33.4 pmol/l (n = 28) in breast
cancer patients (Figure 2C; P = 0.006; 95% confidence
interval = −16.32 to −2.876).Dickkopf-1 is suppressed via inhibition of protein
geranylgeranylation in breast cancer cell lines
We next confirmed whether the observed suppression of
DKK-1 was directly mediated via inhibition of the meva-
lonate pathway. MDA-231 cells were treated with either
zoledronic acid or atorvastatin and were co-treated with
the mevalonate pathway substrates mevalonate, GGPP,
or FPP. In the presence of mevalonate, the effects of
atorvastatin but not of zoledronic acid on DKK-1 were
completely reversed. Supplementation of GGPP fully re-
stored expression of DKK-1 in atorvastatin-treated and
zoledronic acid-treated cells, whereas FPP had no effect
(Figure 3A,B). Substrates alone did not affect DKK-1 ex-
pression (data not shown). As GGPP restores geranyl-
geranylation of proteins and FPP restores farnesylation,
which was confirmed by assessment of RAS and RAP1A
(Figure 3A,B), these results imply that DKK-1 is regu-
lated via inhibited geranylgeranylation. To further verify
this hypothesis, cells were treated with FTI-277 or
GGTI-298, selective inhibitors of farnesyltransferase
or geranylgeranyltransferase I, respectively. Here, only
treatment with GGTI (5 μM) significantly inhibited DKK-1
(Figure 3C). Effects were of comparable magnitude to zo-
ledronic acid, and relevant inhibition of farnesyltransferase
and geranylgeranyltransferase I was confirmed using west-
ern blot analyses of RAS and RAP1A. Of note, treatment
with both zoledronic acid and atorvastatin decreased
intracellular levels of phosphorylated β-catenin, an effect
expected with decreasing DKK-1 levels and suggestive of
increased Wnt signaling (Figure 3D).Cdc42 and Rho are involved in the regulation of
Dickkopf-1
C. difficile toxin A inhibits the GTPases Rho, Rac1 and
Cdc42 [20]. To test whether these geranylgeranylated tar-
get proteins are involved in the regulation of DKK-1,
MDA-231 cells were treated with toxin A. Treatment led
to a significant inhibition of DKK-1 expression (Figure 4A).
To further validate the role of GTPases in BP-induced and
statin-induced DKK-1 suppression, cells were treated with
either zoledronic acid or atorvastatin alone, or in combin-
ation with a GTPase activator (which activates Rho, Rac1
and Cdc42). As expected, single treatment with ator-
vastatin and zoledronic acid suppressed DKK-1 by >80%
(P < 0.001). Activator treatment alone did not signifi-
cantly affect DKK-1 expression, whereas simultaneous
co-treatment with activator and atorvastatin or zoledro-
nic acid largely restored DKK-1 levels in MDA-231 cells
(P < 0.01). These results show that DKK-1 suppression
is regulated via the GTPases Rho, Rac1 and/or Cdc42
(Figure 4B). Further differentiation between these GTPases
was conducted using selective inhibitors. Here, inhib-
ition of Cdc42 and Rho, but not Rac1, resulted in a sig-
nificant suppression of DKK-1 expression and protein
secretion (Figure 4C,D,E). Results were verified with
two different inhibitors, or in the case of Cdc42 using
an inhibitor and siRNA, and results were confirmed in
MDA-bone cells (data not shown). In addition, treat-
ment of cells with Rho-associated protein kinase inhibi-
tors Y-27632 and H-1152P significantly decreased DKK-1
(Figure 4F). Taken together, these results suggest that
mevalonate blockade suppresses DKK-1 via inhibited
geranylgeranylation of Cdc42 and Rho.
Zoledronic acid regulates alkaline phosphatase and
osteoprotegerin in mC2C12 cells by inhibiting Dickkopf-1
in vitro
In the setting of bone metastases, DKK-1 is best known
for its inhibitory effects on osteoblasts and thereby indir-
ectly enhancing osteolytic bone destruction. In addition
to its direct effects on osteoblasts, DKK-1 has also been
reported to inhibit osteoblast-derived OPG production
while promoting receptor activator of nuclear factor-κB
ligand. We used C2C12 cells to investigate effects of
DKK-1 modulation by zoledronic acid on alkaline phos-
phates (ALPs) and bone-protective OPG production. The
presence of WNT3A-containing medium from WTN3A-
overexpressing L-cells induced ALP and OPG production
in C2C12 cells. When co-incubated with supernatants
from different breast cancer cell lines, those with high
baseline levels of DKK-1 inhibited ALP induction by
WNT3A, whereas MCF-7 and T47D cells with low DKK-1
levels had a smaller effect (Figure 5A). Similarly, MCF-7
and T47D were unable to affect WNT3A-induced OPG

























































































































































Figure 3 Dickkopf-1 is regulated via inhibited geranylgeranylation. (A), (B) MDA-231 cells were treated with either zoledronic acid (ZOL;
100 μM) or atorvastatin (ATO; 10 μM) for 24 hours alone or concurrently with mevalonate substrates (geranyl-geranyl-pyrophosphate (GGPP),
farnesyl pyrophosphate (FPP) or mevalonate (MEV)). Dickkopf-1 (DKK-1) was analyzed by polymerase chain reaction (PCR) and enzyme-linked
immunosorbent assay (ELISA). (C) Specific inhibitors of geranylgeranylation GGTI-298 (5 μM) and farnesylation FTI-277 (100 nM) were used for
further pathway clarification, and treatment was for 24 hours. Results of ELISA and PCR data are presented as the mean ± standard deviation of
three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001. Inhibition of geranylgeranylation by GGTI-298, atorvastatin and zoledronic acid,
farnesylation by FTI-277, atorvastatin and zoledronic acid as well as their selective reversal by the substrates was confirmed by assessing
unfarnesylated RAS and ungeranylated RAP1A in western blot. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is used as loading control.
Representative blots are shown. (D) Levels of phosphorylated β-catenin decrease following 24 hours of exposure to zoledronic acid and
atorvastatin. Levels of total β-catenin remain unchanged. GAPDH is used as a loading control.
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demonstrate that WNT3A-mediated induction of an osteo-
blastic phenotype is effectively inhibited by DKK-1, C2C12
cells were treated with increasing concentrations of DKK-1
in the presence of WNT3A (Figures 5B and 6B). DKK-1
dose-dependently decreased ALP and OPG production.
Lower doses of DKK-1 were required to inhibit OPG than
ALP. Furthermore, knocking down DKK-1, as verified by
PCR and enzyme-linked immunosorbent assay, dimin-
ished the ability of MDA-231 cells to inhibit WNT3A-
induced OPG production (Figure 6C). Finally, MDA-
231 cells pretreated with zoledronic acid failed to inhibit
WNT3A-induced ALP and OPG production, an effect
that was fully restored by supplementation of recombin-
ant DKK-1 (Figures 5C and 6D).Dickkopf-1 serum levels decrease in breast cancer
patients receiving adjuvant zoledronic acid
As a proof of principle that DKK-1 is a clinically relevant
target of the mevalonate pathway, we assessed serum
DKK-1 levels in patients with ER-negative and nonmeta-
static breast cancer who received either 4 mg zoledronic
acid (n = 6) or placebo (n = 3) every 3 months. All patients
receiving zoledronic acid showed decreased DKK-1 levels
at 6 and 12 months compared with baseline values. On
average DKK-1 levels were decreased by 60% (± 22.7%
standard deviation) at 12 months, compared with an in-
crease of 44% (± 28% standard deviation) in the placebo
group (Figure 7A; Figure S4B in Additional file 1). Abso-
lute values of DKK-1 were widely spread, ranging from 13

































































































































































Figure 4 Dickkopf-1 is regulated via Cdc42 and Rho in breast cancer. (A) MDA-231 cells were treated for 48 hours with Clostridium difficile
toxin A (250 ng/ml) and assessed for Dickkopf-1 (DKK-1) expression. (B) MDA-231 cells were exposed to zoledronic acid (ZOL) or atorvastatin
(ATO) alone or concurrently with a Rho/Rac/Cdc42 activator for 24 hours. Due to the relatively short half-life of the activator, cells were treated
every 5 hours with 1 μg/ml of activator until cells were harvested after 15 hours. (C) MDA-231 cells were treated with a number of different
GTPase inhibitors for 24 hours and assessed for DKK-1 expression. Concentrations used were 10 μM for Rho#1 and Rho#2, 100 μM for Rac#1,
10 μM for Rac#2 and 50 μM for the Cdc42 inhibitor. (D) MDA-231 cells were transfected with control single interfering RNA (siRNA) or two
different siRNAs directed against Cdc42. Sufficient knockdown was verified by western blot. DKK-1 expression was analyzed 48 hours after
transfection. (E) Regulation of DKK-1 by Cdc42 and Rho was verified at protein levels, by measuring DKK-1 levels in the supernatant of MDA-231
cells treated with the same inhibitors as in C. (F) The role of Rho signaling was further confirmed by measuring DKK-1 levels following 24 hours
of Rho-associated protein kinase inhibition using Y-27632 and H-1152P. Results of enzyme-linked immunosorbent assay and polymerase chain
reaction data are presented as the mean ± standard deviation of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001. GAPDH,
glyceraldehyde 3-phosphate dehydrogenase.
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http://breast-cancer-research.com/content/16/1/R20baseline levels also showed the most rapid decline of
DKK-1 levels after 6 months of treatment. We further
assessed markers of bone turnover in those patients. In
general, BP treatment suppressed biochemical markers of
bone turnover, although in some individuals these changes
were not statistically significant (Figure 7B).
Discussion
We show that DKK-1 is a direct target of the mevalo-
nate pathway (Figure 7C). As an inhibitor of osteoblastdifferentiation and function, elevated DKK-1 levels are
thought to contribute to the imbalance of osteoblastic
bone formation and osteoclastic bone resorption, a pre-
dominant feature in osteolytic bone disease [21]. DKK-1
is best investigated in myeloma bone disease [22] and a
monoclonal antibody, BHQ880, directed against DKK-1
is currently being evaluated in a combined phase I/II
trial [23].
The role of DKK-1 in breast cancerand prostate can-
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Figure 5 Dickkopf-1 inhibits WNT3A-induced osteoblastic differentiation in C2C12 cells. (A) Supernatants of breast cancer cells were harvested
after 48 hours. C2C12 cells were cultured in control medium (containing 50% control L-cell medium) or differentiated in WNT3A-containing media
(50%) and concurrently treated with breast cancer supernatants (25%) or unconditioned control media (25%). C2C12 cells were treated for 48 hours
and assessed for alkaline phosphatase (ALP) expression. (B) C2C12 cells were differentiated with WNT3A media and exposed to increasing
concentrations of recombinant Dickkopf-1 (DKK-1; 10, 50, 100 and 250 ng/ml). (C) C2C12 cells were exposed to supernatants of untreated
or zoledronic acid-treated MDA-231 cells in the presence of WNT3A. To prevent potential direct effects of zoledronic acid on C2C12 cells,
MDA-231 cells were preincubated with zoledronic acid for 24 hours, media were then replaced and zoledronic acid-free supernatants were
harvested 48 hours later. Results of polymerase chain reaction data are presented as the mean ± standard deviation of three independent
experiments. *P < 0.01; ***P < 0.001.
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http://breast-cancer-research.com/content/16/1/R20predominantly osteolytic lesions are found, a mechanism
similar to that proposed in multiple myeloma is plausible.
In this study, we identified an increased expression of
DKK-1 in hormone-negative and highly osteotropic breast
cancer cell lines. This subtype is particularly associated
with an unfavorable outcome and a high risk of recur-
rence. Therefore, adjuvant treatments decreasing the risk
of relapse are warranted. Assessment of primary tissue re-
vealed an overexpression of DKK-1 in ER-negative breast
cancer cases, but the expression appears independent of
tumor grade or stage. Moreover, our data show that breast
cancer-derived DKK-1 potently inhibits osteoblast differ-
entiation, as seen assessed by ALP expression, as well as
osteoblast-derived production of OPG, a potent inhibitor
of osteoclast activity. Zoledronic acid prevented this osteo-
blast inhibition by negative regulation of DKK-1. This
novel mechanism may help to consolidate bone turnover
in the metastatic process and provides a rationale to fur-
ther explore the adjuvant use of BPs in patients with high
DKK-1 levels.
In contrast to breast cancer, bone metastases from
prostate cancers are predominantly osteosclerotic [24].
Here, the role of DKK-1 is less obvious. DKK-1 levels
have been described to increase early in disease devel-
opment, followed by a decrease with tumor progression
and bone metastases, which may depict the molecular
switch that transitions the osteolytic phenotype to an
osteoblastic phenotype [17]. This concept is supported by
the finding that overexpression of DKK-1 in osteoblasticprostate cancer cells induces an osteolytic phenotype [25].
In line with these findings, only the osteolytic PC3 cells
expressed relevant levels of DKK-1 in this report. Lower-
ing DKK-1 levels may have direct practical implications
for patients with osteotropic tumors because osteoblast
activity may be normalized directly and indirectly via OPG
and receptor activator of nuclear factor-κB ligand signal-
ing. Silencing of DKK-1 delayed the development of bone
lesions in a model of prostate cancer [26], and neutralizing
DKK-1 antibodies have been successfully applied to pre-
vent bone lesions in a preclinical model of myeloma bone
disease [13]. Besides the promising effects of DKK-1 inhib-
ition on bone metastases, inhibiting DKK-1 also bears the
potential risk of promoting tumor proliferation as a result
of activated Wnt signaling and a number of studies have
defined DKK-1 as a tumor suppressor [27-29]. However,
these studies focused on effects of overexpressing DKK-1
mainly in hormone receptor-positive breast cancer cells
with low or undetectable baseline levels of DKK-1, and
these results may not be transferable to other breast
cancer subtypes and other entities. Indeed, DKK-1-
overexpressing prostate cancer cells were recently re-
ported to have an increased subcutaneous tumor mass
upon ectopic transplantation and a higher incidence of
bone metastases after intracardiac injection [30]. Fur-
thermore, genetic disorders of dysfunctional Wnt inhib-
itors, such as van Buchem’s disease and sclerosteosis,
are not associated with an increased risk of malignan-
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Figure 6 Dickkopf-1 inhibits WNT3A-induced osteoprotegerin production in C2C12 cells. (A) Supernatants of breast cancer cells were
harvested after 48 hours. C2C12 cells were cultured in control medium (containing 50% control L-cell medium) or differentiated in WNT3A-containing
media (50%) and concurrently treated with breast cancer supernatants (25%) or unconditioned control media (25%). C2C12 cells were treated for
48 hours and assessed for osteoprotegerin (OPG) expression and protein secretion. (B) C2C12 cells were differentiated with WNT3A media and
exposed to increasing concentrations of recombinant Dickkopf-1 (DKK-1; 10, 50, 100 and 250 ng/ml). (C) DKK-1 was transiently knocked down
in MDA-231 cells using two different single interfering RNAs (siRNAs). Knockdown was verified by quantifying DKK-1 levels secreted into the
supernatant 48 hours after transfection. Supernatants of control siRNA and DKK-1 siRNA-treated cells were given to C2C12 cells during
WNT3A-induced differentiation in the established ratios of 25% and 50%. OPG levels were determined after 48 hours of exposure. (D) C2C12
cells were exposed to supernatants of untreated or zoledronic acid-treated MDA-231 cells in the presence of WNT3A. To prevent potential
direct effects of zoledronic acid on C2C12 cells, MDA-231 cells were preincubated with zoledronic acid for 24 hours, media were then
replaced and zoledronic acid-free supernatants were harvested 48 hours later. Suppressed DKK-1 levels in the supernatant were confirmed
by enzyme-linked immunosorbent assay (ELISA) prior to use. Results of ELISA and polymerase chain reaction data are presented as the
mean ± standard deviation of three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001.
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sclerostin) in patients with existing malignancies, and the
potential risk of aggravation should be considered.
In our study, inhibition of the mevalonate pathway re-
sulted in a profound suppression of DKK-1 in vitro and in
breast cancer patients receiving zoledronic acid. We have
previously shown that similar concentrations of zoledronic
acid are sufficient to induce apoptosis in treated cancer
cells [32,33]. Furthermore, decreased vascular endothelial
growth factor levels have been reported in women receiv-
ing zoledronic acid [34]. Recent results from two large
clinical trials have yielded inconclusive results regarding
the general use of zoledronic acid as an adjuvant therapy
for breast cancer patients [6,7]. While especially postmen-
opausal women appeared to benefit from early treatment
with zoledronic acid, exact characteristics of these groups
remain elusive. More recently, a meta-analysis of three
placebo-controlled trials underlined better survival forzoledronic acid treatment of patients with bone metastases
from solid tumors who displayed poor prognosis features
such as elevated NTX levels as a surrogate for aggressive
bone lesions [35]. Here, we found an overexpression of
DKK-1 in ER-negative breast cancer patients. This is in
line with another study, which reported a relative increase
of DKK-1 in ER/progesterone receptor-negative cancer
[15]. In our patients, baseline levels of DKK-1 largely var-
ied. This limits the use of DKK-1 as a potential screening
marker. Also, it remains unclear whether increases in
DKK-1 during the course of a disease are associated with
tumor progression. Elevated DKK-1 levels are described in
breast cancer patients with confirmed bone lesions [14]
and a recent study defined high levels of DKK-1 as a nega-
tive prognostic marker in triple-negative breast cancer
[16]. It is therefore feasible that lowering DKK-1 levels
may have positive effects. Hence, patients with high


































































































Figure 7 Dickkopf-1 levels are suppressed in women with breast cancer following zoledronic acid. (A) Dickkopf-1 (DKK-1) levels were
measured in women with estrogen receptor (ER)-negative nonmetastatic breast cancer, who received 3-monthly infusions of zoledronic acid
(ZOL; n = 6) or placebo (n = 3). DKK-1 levels are presented as mean absolute values and mean percentage of baseline expression. (B) Markers of
bone turnover were assessed at the same time points as DKK-1. Values are presented as percentage of baseline expression. (C) Schematic
regulation of DKK-1 by mevalonate pathway modulators via inhibition of Cdc42 and Rho. ALP, alkaline phosphatase; CTx, C-terminal telopeptide;
IPP, isopentenyl pyrophosphate; TRAP, tartrate-resistant acid phosphatase; PP, pyrophosphate.
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http://breast-cancer-research.com/content/16/1/R20therapy with zoledronic acid or potentially another
mevalonate pathway inhibitor. We found DKK-1 levels
to remain effectively suppressed for at least 12 months.
Whereas zoledronic acid is a standard agent for the
treatment of established bone metastases, statins are
not used in this context. In vitro, considerably lower
concentrations of atorvastatin than zoledronic acid were
needed to achieve a comparable suppression of DKK-1.
However, whether the use of statins also translates into
a clinically relevant suppression of DKK-1, as seen with
zoledronic acid, remains unclear.
Our study has potential limitations. The number of
patients included in this study is small and we have no
available survival data. Larger clinical trials are therefore
needed to fully define the prognostic value and patho-
physiological role of DKK-1 in breast cancer. Further-
more, the tissue or cellular source of DKK-1 suppression
remains unclear. Women received zoledronic acid as an
adjuvant treatment and were tumor free. The drop in
DKK-1 is unlikely to stem from the removal of thetumor, because there was no decrease in the placebo-
treated group. Bone markers in the zoledronic acid-
treated patients are suppressed as expected following
antiresorptive treatment. The decrease in serum DKK-1
may therefore be explained by an impaired osteoblastic
activity. Alternatively, since cells of vascular origin are
also sensitive to zoledronic acid, DKK-1 suppression
may also be a cumulative effect derived from multiple
cell types.
Furthermore, the doses required to suppress DKK-1
in vitro probably exceed achievable serum concentra-
tions in vivo. Serum concentrations of zoledronic acid
decline rapidly after infusion and, although we have
shown that a short exposure time of 2 hours is sufficient
to mimic the effects of a continuous BP exposure on
DKK-1, it remains unclear whether the observed effects
in breast cancer cells in vitro can be translated into the
clinical setting. BP uptake in vitro is likely to be medi-
ated by fluid phase endocytosis and the cells’ ability to
interfere with the mevalonate pathway in cellular targets
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http://breast-cancer-research.com/content/16/1/R20outside the bone is likely to be limited by availability and
other pharmacokinetic properties.
Currently, it remains unclear to what extent the DKK-1
serum pool in breast cancer patients affected by bone
metastasis is derived from tumor cells versus reactively
enhanced bone remodeling and whether the suppression
of DKK-1 by zoledronic acid has a beneficial effect on
osteoblast/osteoclast activity at the site of an established
bone lesion or might even prevent the establishment of
disseminated tumor cells in the bone.
Conclusion
We show that zoledronic acid and atorvastatin, two clinic-
ally approved inhibitors of the mevalonate pathway, effect-
ively inhibit the Wnt inhibitor DKK-1 in breast cancer
cells and, thereby, prevent the inhibition of WNT3A-
induced OPG production in osteoblasts in vitro. These
findings warrant further studies on DKK-1 in osteolytic
bone disease and mevalonate pathway inhibitors in breast
cancer.
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Additional file 1: Figure S1. (A) results from a Wnt signaling pathway
PCR array conducted with MDA-231 breast cancer cells after 24 hours of
treatment with zoledronic acid. Genes with >2-fold regulation are black.
(B) Baseline expression of DKK-1 in osteolytic PC3 and osteoblastic
MDA-PCa 2b prostate cancer cells. PC3 cells treated with zoledronic acid
(100 μM) or atorvastatin (10 μM) for 24 hours. (C), (D) Human microvascu-
lar endothelial cells-1 and human umbilical vein endothelial cells after
24 hours with zoledronic acid (100 μM), atorvastatin (10 μM), GGTI-298
(5 μM) or FTI-277 (100 nM). PCR data presented as the mean ± standard
deviation (SD) of three independent experiments. Figure S2. MDA-231
cells were exposed to increasing doses of zoledronic acid (A) or atorvastatin
(B) for 24 hours. (C) MDA-231 cells were exposed to zoledronic acid for
2 hours. After 2 hours, media were removed, cells were washed twice and
fresh media were added. After an additional 24 hours RNA was isolated and
DKK-1 expression was assessed. Data are presented as the mean ± SD of
three independent experiments. Figure S3. (A) validation of DKK-1 antibody
staining. MDA-231 cells treated with DKK-1 siRNA or control siRNA, pelleted
and embedded in paraffin. Cells were stained with the DKK-1 antibody used
for the tissue microarray. No staining was detectable in MDA-231 cells with
depleted DKK-1, whereas a strong staining was detectable in control
siRNA-treated cells. (B) Patient characteristics of control and breast cancer
cohort assessed in Figure 2C. Patients were matched for age, size, weight,
menarche, and menopausal status. Figure S4. (A) patient characteristics of
Figure 7, and (B) individual absolute and relative DKK-1 values of breast
cancer patients receiving adjuvant zoledronic acid or placebo every
3 months. Serum DKK-1 was measured at baseline, 6 and 12 months.
Mean values of placebo and zoledronic acid treated patients are shown
in Figure 7A.
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